Literature DB >> 10674068

Mycobacterium ulcerans disease; Buruli ulcer.

H S Thangaraj1, M R Evans, M H Wansbrough-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10674068     DOI： 10.1016/s0035-9203(99)90104-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


× No keyword cloud information.
  21 in total

1.  Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Authors:  Marie-Thérèse Ruf; Daniela Schütte; Aurélie Chauffour; Vincent Jarlier; Baohong Ji; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Contours of risk: spatializing human behaviors to understand disease dynamics in changing landscapes.

Authors:  Heidi Hausermann; Petra Tschakert; Erica A H Smithwick; David Ferring; Richard Amankwah; Erasmus Klutse; Julianne Hagarty; Lindsay Kromel
Journal:  Ecohealth       Date:  2012-07-18       Impact factor: 3.184

4.  A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans.

Authors:  T Stinear; J K Davies; G A Jenkin; F Portaels; B C Ross; F Oppedisano; M Purcell; J A Hayman; P D Johnson
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone.

Authors:  Alexa K Daniel; Richard E Lee; Francoise Portaels; P L C Small
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides.

Authors:  R Phillips; O Adjei; S Lucas; N Benjamin; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  New anti-tuberculosis agents amongst known drugs.

Authors:  Kathryn E A Lougheed; Debra L Taylor; Simon A Osborne; Justin S Bryans; Roger S Buxton
Journal:  Tuberculosis (Edinb)       Date:  2009-08-20       Impact factor: 3.131

9.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Authors:  Ghislaine Prévot; Eliane Bourreau; Herve Pascalis; Roger Pradinaud; Audrey Tanghe; Kris Huygen; Pascal Launois
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  A Landscape-based model for predicting Mycobacterium ulcerans infection (Buruli Ulcer disease) presence in Benin, West Africa.

Authors:  Tyler Wagner; M Eric Benbow; Meghan Burns; R Christian Johnson; Richard W Merritt; Jiaguo Qi; Pamela L C Small
Journal:  Ecohealth       Date:  2008-02-08       Impact factor: 3.184
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.